CORC

在结果中检索

CORC

浏览/检索结果: 共32条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
Efficacy and safety of IBI305 compared with bevacizumab in advanced non-squamous NSCLC patients as first-line treatment in a randomized, double-blind, phase III study. 会议论文
作者:  Zhang, Li;  Wu, Bin;  Huang, Linian;  Shi, Meiqi;  Liu, Yunpeng
收藏  |  浏览/下载：20/0  |  提交时间：2019/12/05
Efficacy and safety of IBI305 compared with bevacizumab in advanced non-squamous NSCLC patients as first-line treatment in a randomized, double-blind, phase III study. 会议论文
作者:  Zhang, Li;  Wu, Bin;  Huang, Linian;  Shi, Meiqi;  Liu, Yunpeng
收藏  |  浏览/下载：12/0  |  提交时间：2019/12/05
Circulating DNA-Based Sequencing Guided Anlotinib Therapy in Non-Small Cell Lung Cancer 期刊论文
2019, 卷号: 6, 期号: 19, 页码: 1900721
作者:  Lu Jun;  Zhong Hua;  Wu Jun;  Chu Tianqing;  Zhang Lele
收藏  |  浏览/下载：13/0  |  提交时间：2020/01/03
Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment 期刊论文
CANCER BIOLOGY & MEDICINE, 2018, 卷号: 15, 期号: 4
作者:  Wang, Jing;  Zhao, Yizhuo;  Wang, Qiming;  Zhang, Li;  Shi, Jianhua
收藏  |  浏览/下载：3/0  |  提交时间：2019/12/04
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer The ALTER 0303 Phase 3 Randomized Clinical Trial 期刊论文
JAMA ONCOLOGY, 2018, 卷号: 4, 期号: 11
作者:  Han, Baohui;  Li, Kai;  Wang, Qiming;  Zhang, Li;  Shi, Jianhua
收藏  |  浏览/下载：3/0  |  提交时间：2019/12/04
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. 期刊论文
JAMA Oncology, 2018, 卷号: 4, 期号: 11, 页码: 1569-1575
作者:  Han, Baohui*;  Li, Kai*;  Wang, Qiming;  Zhang, Li;  Shi, Jianhua
收藏  |  浏览/下载：7/0  |  提交时间：2019/12/03
Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302) 期刊论文
British Journal of Cancer, 2018, 卷号: 118, 期号: 5, 页码: 654-661
作者:  Han, Baohui*;  Li, Kai;  Zhao, Yizhuo;  Li, Baolan;  Cheng, Ying
收藏  |  浏览/下载：9/0  |  提交时间：2019/12/03
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. 期刊论文
JAMA oncology, 2018, 卷号: 4, 页码: 1569-1575
作者:  Han Baohui;  Li Kai;  Wang Qiming;  Zhang Li;  Shi Jianhua
收藏  |  浏览/下载：5/0  |  提交时间：2019/11/26
Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment 期刊论文
CANCER BIOLOGY & MEDICINE, 2018, 卷号: 15, 页码: 443-451
作者:  Wang, Jing;  Zhao, Yizhuo;  Wang, Qiming;  Zhang, Li;  Shi, Jianhua
收藏  |  浏览/下载：5/0  |  提交时间：2019/11/26
Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer 期刊论文
LUNG CANCER, 2018, 卷号: 122, 页码: 32-37
作者:  Si, Xiaoyan;  Zhang, Li;  Wang, Hanping;  Zhang, Xiaotong;  Wang, Mengzhao
收藏  |  浏览/下载：3/0  |  提交时间：2019/11/26

©版权所有 ©2017 CSpace - Powered by CSpace